We are monitoring the impact of COVID-19 on North America HIV Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1981
Share on
Share on

North America HIV Therapeutics Market Research Report – Segmented By Type, Application and Country (United States, Canada and Rest of North America) – Industry Size, Share, Growth, Trends and Forecast | 2019 - 2024

Pulished: February, 2020
ID: 1981
Pages: 118

The size of the North American HIV Therapeutics Market was worth USD 5.4 billion in 2019 and estimated to be growing at a CAGR of 1.1%, to reach USD 5.7 billion by 2024.

The human immunodeficiency virus (HIV) refers to a kind of retrovirus that causes (AIDS). HIV affects some immune cells and it weakens the immune system bringing about loss of capacity to fight against the organisms that cause diseases.

HIV spreads through the exchange of fluids with some infected individual, for example, blood exchange or imparting needles to somebody who is HIV infected. What's more, HIV can spread from infected mother to child during pregnancy. Here are some of the symptoms of HIV disease are weakness, slight fever, swollen glands, cerebral pains and muscle hurts.

Major factors driving the North American HIV Therapeutics Market are Increasing the number of HIV affected cases, an innovative advancement in HIV diagnosis and therapeutics, ascend in research exercises for developing HIV immunizations and not aware of the methods of transmission of the infection. Moreover, increasing awareness about the accessibility of HIV therapeutics in the market and cost-effective sedate treatments for HIV are driving the worldwide North American HIV Therapeutics Market.

Be that as it may, different variables, for example, the disappointment of treatment sometimes, absence of gifted experts and presentation of non-specific medications in the market are major restraints the North American HIV Therapeutics Market.

This research report is segmented &b sub-segmented the market into the following categories:

  • By Type: Nucleoside/Tide Reverse Transcriptase Inhibitors, Nucleoside/Tide Analogues, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors, CCR5 Inhibitors and Fusion Inhibitors
  • By Application: HIV Type-1 and HIV Type-2
  • By Country: United States, Canada and Rest of North America

Top companies operating in the North American HIV Therapeutics Market profiled in this report are GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Merck, Hoffmann-La Roche and Gilead Sciences.


                1.1 Market Definition                                                                    

                1.2 Study Deliverables                                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                                          

                1.4 General Study Assumptions                                                                

2. Research Methodology                                                                                           

                2.1 Introduction                                                                               

                2.2 Research Phases                                                                      

                                2.2.1 Secondary Research                                                           

                                2.2.2 Primary Research                                                 

                                2.2.3 Econometric Modelling                                                      

                                2.2.4 Expert Validation                                                  

                2.3 Analysis Design                                                                         

                2.4 Study Timeline                                                                          

3. Overview                                                                                       

                3.1 Executive Summary                                                                

                3.2 Key Inferences                                                                         

                3.3 Epidemology                                                                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                                    

                4.1 Market Drivers                                                                          

                4.2 Market Restraints                                                                    

                4.3 Key Challenges                                                                         

                4.4 Current Opportunities in the Market                                                                              

5. Market Segmentation                                                                                              

                5.1 Drug Class                                                                   

                                5.1.1 Introduction                                                           

                                5.1.2 integrase inhibitor                                                               

                                5.1.3 nucleoside/nucleotide reverse transcriptase inhibitor                                                         

                                5.1.4  non-nucleoside turn around transcriptase inhibitor                                                             

                                5.1.5 HIV-1 protease inhibitor                                                    

                                5.1.6 pharmacokinetic enhancer                                                              

                                5.1.7 passage inhibitor                                                  

                                5.1.8  Y-o-Y Growth Analysis, Drug class                                                                

                                5.1.9  Market Attractiveness Analysis, Drug class                                                              

                                5.1.10  Market Share Analysis, Drug class                                                              

                5.2 Application                                                                 

                                5.2.1 Introduction                                                           

                                5.2.2 HIV Type-1                                                              

                                5.2.3 HIV Type-2                                                              

                                5.2.4 Y-o-Y Growth Analysis, Application                                                               

                                5.2.5 Market Attractiveness Analysis, Application                                                             

                                5.2.6 Market Share Analysis, Application                                                              

6. Geographical Analysis                                                                                              

                6.1 Introduction                                                                               

                                6.1.1 Regional Trends                                                    

                                6.1.2 Impact Analysis                                                     

                                6.1.3 Y-o-Y Growth Analysis                                                        

                                       By Geographical Area                                     

                                       Drug Class                                            

                                       HIV TYPE 1&2                                      

                                6.1.4  Market Attractiveness Analysis                                                     

                                       By Geographical Area                                     

                                       Drug Class                                            

                                       HIV TYPE 1&2                                      

                                6.1.5  Market Share Analysis                                                      

                                       By Geographical Area                                     

                                       Drug Class                                            

                                       HIV TYPE 1&2                                      

                6.2 United States                                                                            

                6.3 Canada                                                                         

7.Strategic Analysis                                                                                        

                7.1 PESTLE analysis                                                                         

                                7.1.1 Political                                                     

                                7.1.2 Economic                                                 

                                7.1.3 Social                                                         

                                7.1.4 Technological                                                         

                                7.1.5 Legal                                                          

                                7.1.6 Environmental                                                       

                7.2 Porter’s Five analysis                                                                              

                                7.2.1 Bargaining Power of Suppliers                                                        

                                7.2.2 Bargaining Power of Consumers                                                    

                                7.2.3 Threat of New Entrants                                                     

                                7.2.4 Threat of Substitute Products and Services                                                              

                                7.2.5 Competitive Rivalry within the Industry                                                     

8.Market Leaders' Analysis                                                                                         

                8.1 Athersys                                                                      

                                8.1.1 Overview                                                 

                                8.1.2 Product Analysis                                                   

                                8.1.3 Financial analysis                                                  

                                8.1.4 Recent Developments                                                       

                                8.1.5 SWOT analysis                                                       

                                8.1.6 Analyst View                                                          

                8.2 StemCells                                                                    

                8.3 Cryo Cell International                                                                           

                8.4 Geron Corporation                                                                  

                8.5 Mesoblast                                                                   

                8.6 Aastrom Biosciences                                                                              

                8.7 Celgene Corporation                                                                              

                8.8 Invitrogen                                                                   

                8.9 Cytori Therapeutics                                                                 

                8.10 Retractable Technologies                                                                   

9.Competitive Landscape                                                                                            

                9.1 Market share analysis                                                                            

                9.2 Merger and Acquisition Analysis                                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                                         

                9.4 New Product Launches                                                                         

10.Market Outlook and Investment Opportunities                                                                                          


                a) List of Tables                                                                

                b) List of Figures                                                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America HIV Therapeutics Market By Type, From 2019 - 2024 ( USD Million )
  2. North America Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market By Region, From 2019 - 2024 ( USD Million )
  3. North America Non-nucleoside reverse transcriptase inhibitors Market By Region, From 2019 - 2024 ( USD Million )
  4. North America Protease inhibitors Market By Region, From 2019 - 2024 ( USD Million )
  5. North America Integrase [strand transfer] inhibitors Market By Region, From 2019 - 2024 ( USD Million )
  6. North America Fusion inhibitors Market By Region, From 2019 - 2024 ( USD Million )
  7. North America HIV Therapeutics Market By Application, From 2019 - 2024 ( USD Million )
  8. North America HIV Type 1 Market By Region, From 2019 - 2024 ( USD Million )
  9. North America HIV Type 2 Market By Region, From 2019 - 2024 ( USD Million )
  10. United States HIV Therapeutics Market By Type, From 2019 - 2024 ( USD Million )
  11. United States HIV Therapeutics Market By Application, From 2019 - 2024 ( USD Million )
  12. Canada HIV Therapeutics Market By Type, From 2019 - 2024 ( USD Million )
  13. Canada HIV Therapeutics Market By Application, From 2019 - 2024 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports


$ 1234 3335

Click for Request Sample